AptarGroup, Inc. (ATR)
| Market Cap | 7.25B -27.5% |
| Revenue (ttm) | 3.87B +8.9% |
| Net Income | 386.67M +4.4% |
| EPS | 5.85 +7.0% |
| Shares Out | 63.82M |
| PE Ratio | 19.41 |
| Forward PE | 20.02 |
| Dividend | $1.92 (1.69%) |
| Ex-Dividend Date | May 6, 2026 |
| Volume | 575,790 |
| Open | 115.89 |
| Previous Close | 115.81 |
| Day's Range | 112.45 - 116.04 |
| 52-Week Range | 103.23 - 164.28 |
| Beta | 0.42 |
| Analysts | Buy |
| Price Target | 163.29 (+43.73%) |
| Earnings Date | Apr 30, 2026 |
About ATR
AptarGroup, Inc. designs and manufactures drug delivery, consumer product dispensing, and active material science solutions and services for the pharmaceutical, fragrance, facial skincare, color cosmetics, personal care, home care, and food and beverage markets. The company operates through three segments: Pharma, Beauty, and Closures. It provides dispensing pumps used to dispense sprays, liquids, or lotions from non-pressurized containers; fine-mist pumps for pharmaceutical and fragrance applications; and lotion pumps for viscous formulations,... [Read more]
Financial Performance
In 2025, AptarGroup's revenue was $3.78 billion, an increase of 5.42% compared to the previous year's $3.58 billion. Earnings were $392.79 million, an increase of 4.87%.
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for ATR stock is "Buy." The 12-month stock price target is $163.29, which is an increase of 43.73% from the latest price.
News
AptarGroup Sets CEO Succession as 2025 Sales Rise and Shareholders Back Ballot
AptarGroup NYSE: ATR used its annual meeting to announce a planned chief executive transition, report that shareholders approved all items on the ballot and provide an update on 2025 performance and e...
AptarGroup Transcript: AGM 2026
The meeting confirmed leadership succession, approved all voting items, and highlighted strong 2025 financial results, including increased sales and dividends. Strategic focus remains on Pharma growth, sustainability, and operational efficiency.
Advanced Technology Recycling (ATR) Announces That They Are Now Offering Wholesale Electronics to the General Public Through Their Online Auction Site
ITAD Firm, Advanced Technology Recycling (ATR), now offers wholesale electronics and computers to the general public through our online auction platform.
AptarGroup price target raised to $145 from $144 at Wells Fargo
Wells Fargo analyst Gabe Hajde raised the firm’s price target on AptarGroup (ATR) to $145 from $144 and keeps an Overweight rating on the shares. While the firm acknowledges the…
AptarGroup Earnings Call Transcript: Q1 2026
Sales rose 11% year-over-year, but core sales were flat as emergency medicine destocking weighed on pharma. Beauty and closures saw margin pressure from mix and operational issues, but sequential improvements are expected. Free cash flow doubled and $131 million was returned to shareholders.
AptarGroup Earnings release: Q1 2026
AptarGroup released its Q1 2026 earnings on May 1, 2026, summarizing the period's financial results.
AptarGroup Slides: Q1 2026
AptarGroup has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 1, 2026.
AptarGroup Quarterly report: Q1 2026
AptarGroup has published its Q1 2026 quarterly earnings report on May 1, 2026.
AptarGroup reports Q1 EPS $1.19, consensus $1.15
Reports Q1 revenue $982.9M, consensus $955.9M. “Across the broader Pharma portfolio, we continue to see growing demand in key areas including GLP-1 therapies, biologics, systemic nasal drug delivery, ...
AptarGroup sees Q2 EPS $1.32-$1.40, consensus $1.34
Regarding Aptar’s outlook, CEO Tanda stated, “Looking ahead to Q2, excluding destocking in emergency medicine within Pharma, we anticipate a solid quarter with growth across each segment. Outside of t...
Aptar Reports First Quarter 2026 Results
CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--Aptar Reports First Quarter 2026 Results.
Aptar Declares Quarterly Dividend
CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--Aptar Declares Quarterly Dividend.
Aptar Digital Health Partners with Enable Injections for enFuse® Companion Digital Solution
CINCINNATI, April 08, 2026 (GLOBE NEWSWIRE) -- Aptar Digital Health, a global leader in digital health solutions enhancing the patient experience, and Enable Injections, Inc. (“Enable”), a healthcare ...
AptarGroup price target lowered to $145 from $147 at BofA
BofA analyst George Staphos lowered the firm’s price target on AptarGroup (ATR) to $145 from $147 and keeps a Neutral rating on the shares as part of the firm’s preview…
AptarGroup Proxy statement: Proxy filing
AptarGroup filed a proxy statement on March 27, 2026, providing details for shareholder voting and corporate governance matters.
AptarGroup Proxy statement: Proxy filing
AptarGroup filed a proxy statement on March 27, 2026, providing details for shareholder voting and corporate governance matters.
AptarGroup upgraded to Overweight from Equal Weight at Wells Fargo
Wells Fargo upgraded AptarGroup (ATR) to Overweight from Equal Weight with a price target of $144, up from $133. The firm says the share price reaction relating to the Iran…
AptarGroup’s unidose powder nasal delivery system used in ENA Phase 2 study
The company states: “AptarGroup (ATR) announced that its Unidose Powder Nasal Spray System is being utilized in ENA Respiratory’s Phase II clinical study of INNA 051, an investigational nasal spray…
AptarGroup CEO Stephan Tanda to retire, Gael Touya to succeed
AptarGroup (ATR) announced that Gael Touya, most recently Aptar Pharma president, has been appointed president and CEO, effective September 1. He will succeed Stephan Tanda, who has served as presiden...
Aptar Announces Gael Touya as its Next Chief Executive Officer; Stephan B. Tanda to Retire by the End of the Year
CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--Aptar Announces Gael Touya as its Next President and Chief Executive Officer; Stephan B. Tanda to Retire by the End of the Year.
AptarGroup Transcript: 47th Annual Raymond James Institutional Investor Conference
A global leader in drug and consumer product dispensing, the company reported $3.8 billion in 2025 revenue, with pharma as its core growth engine. Strong innovation, a diversified pipeline, and sustainability leadership support long-term growth, with margin improvements expected across all segments in 2026.
AptarGroup Slides: 47th Annual Raymond James Institutional Investor Conference
AptarGroup has posted slides in relation to its latest quarterly earnings report, which was published on March 3, 2026.
AptarGroup Transcript: Bank of America 2026 Global Agriculture and Materials Conference
Proprietary drug delivery systems are expanding into new therapeutic areas, with strong growth in injectables and consumer businesses. Operational improvements and regional strategies, especially in China, support resilience. Margin expansion is expected as capacity investments and product mix evolve.
AptarGroup Slides: FY 2026
AptarGroup has posted slides in relation to its FY 2026 quarterly earnings report, which was published on February 25, 2026.
Aptar to Participate in Upcoming Investor Conferences
CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--Aptar to Participate in Upcoming Investor Conferences.